Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M, Tamiya A, Kaneda H, Nakagawa K, Yoh K, Goto K, Okamoto H, Shimokawa T, Abe T, Tanaka H, Daga H, Takeda K, Hirashima T, Atagi S. Tamiya M, et al. Among authors: kaneda h. Med Oncol. 2016 Jan;33(1):2. doi: 10.1007/s12032-015-0715-7. Epub 2015 Nov 24. Med Oncol. 2016. PMID: 26603297 Clinical Trial.
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, Fukino K, Tanigawa T, Nakagawa K. Okamoto I, et al. Among authors: kaneda h. Invest New Drugs. 2010 Dec;28(6):844-53. doi: 10.1007/s10637-009-9321-x. Epub 2009 Sep 18. Invest New Drugs. 2010. PMID: 19760364 Free PMC article. Clinical Trial.
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Kaneda H, Okamoto I, Hayashi H, Yoshioka H, Miyazaki M, Kudoh S, Kimura T, Sugiura T, Sawa T, Takeda K, Iwamoto Y, Satouchi M, Akita K, Saito H, Goto I, Shibata K, Fukuoka M, Nakagawa K; West Japan Thoracic Oncology Group. Kaneda H, et al. J Thorac Oncol. 2010 Jan;5(1):105-9. doi: 10.1097/JTO.0b013e3181c07c6c. J Thorac Oncol. 2010. PMID: 19884859 Free article. Clinical Trial.
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.
Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K. Okamoto I, et al. Among authors: kaneda h. Mol Cancer Ther. 2010 Oct;9(10):2825-33. doi: 10.1158/1535-7163.MCT-10-0379. Epub 2010 Aug 5. Mol Cancer Ther. 2010. PMID: 20688946 Clinical Trial.
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K. Azuma K, et al. Among authors: kaneda h. Biochem Biophys Res Commun. 2011 Apr 1;407(1):219-24. doi: 10.1016/j.bbrc.2011.03.002. Epub 2011 Mar 4. Biochem Biophys Res Commun. 2011. PMID: 21377448
611 results